Halicin: deep learning identifies an antibiotic
A model trained on about 2,500 molecules screened the roughly 6,000 compounds in the Broad Institute’s Drug Repurposing Hub and identified halicin, which killed many resistant bacteria in the lab and cleared A. baumannii infections in mice within 24 hours. Cell-culture and mouse results, not human studies; the mechanism remains preliminary.
Technology: Graph neural network for predicting antibacterial activity
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Bactericidal activity against a wide range of pathogens, including M. tuberculosis and carbapenem-resistant Enterobacteriaceae; halicin treated C. difficile and pan-resistant A. baumannii infections in mice. Of 23 tested predictions from over 107 million ZINC15 molecules, eight were antibacterial.
- Still unknown: Human safety and efficacy are not reported in the abstract.
- AI role: A deep neural network predicted antibacterial activity across chemical libraries; candidates were then tested experimentally.
Evidence sources: https://doi.org/10.1016/j.cell.2020.01.021
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Original institutional announcement checked for the specific results, AI contribution and limitations cited in the antibiotic dossier or mathematical follow-up pilot. Full-paper reanalysis, external replication and an exhaustive follow-up search were not performed..
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 2730 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
- same-team extension · 25 May 2023: MIT describes abaucin as a subsequent application of the antibiotic-screening program to A. baumannii. This is a different candidate and target-specific study, not replication of halicin. Source. Recorded 16 Nov 2026.
- same-team extension · 14 Aug 2025: MIT identifies halicin and abaucin as earlier screening results motivating generative design of new NG1/DN1 candidates. The later study does not establish clinical efficacy of these earlier candidates. Source. Recorded 16 Nov 2026.
Follow-up checked 16 Nov 2026 within scope: Bounded check of the original announcements cited by the events recorded here, including explicit links to later program work. This is not an exhaustive literature search or ongoing monitoring commitment..
No source-supported relationships recorded.